← Human Trials & Peer-Reviewed Studies
Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects.
Plain-language guide to PMID 25210879 (2014): double-blind randomized controlled trial of Glucagon, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 25210879
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Trahair LG et al. (6 authors)
- DOI
- 10.1210/jc.2014-2475
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glucagon in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.
To determine whether exogenous GLP-1 modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR, and splanchnic blood flow in healthy older subjects.
Why It Was Studied
Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR).
Who Took Part
By PubMed's age tags, the people studied were older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.
As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.
A double-blind randomized trial was conducted.
Community-dwelling residents attended a clinical research laboratory.
Between t = 0-60 min, ID glucose was infused at 3 kcal/min.
What Was Measured
The subject headings attached to it are Autonomic Nervous System, Blood Glucose, Blood Pressure, Duodenum, Glucagon-Like Peptide 1, Glucose and Heart Rate.
What This Means in Plain Language
The paper is a randomized and double-blind study of Glucagon in people with low blood pressure and orthostatic hypotension.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Glucagon compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.